{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Nasal+Cavity+Squamous+Cell+Carcinoma", "query": { "condition": "Metastatic Nasal Cavity Squamous Cell Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 121, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Nasal+Cavity+Squamous+Cell+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T19:21:44.048Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01528137", "title": "Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IVA Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Salivary Gland Cancer", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Salivary Gland Cancer", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Tongue Cancer" ], "interventions": [ { "name": "talactoferrin", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2012-05", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2016-08-02", "last_synced_at": "2026-06-25T19:21:44.048Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01528137" }, { "nct_id": "NCT01334177", "title": "TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Tongue Cancer" ], "interventions": [ { "name": "TLR8 agonist VTX-2337", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2011-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-03-05", "last_synced_at": "2026-06-25T19:21:44.048Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01334177" }, { "nct_id": "NCT00503997", "title": "Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2006-12", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2012-05-10", "last_synced_at": "2026-06-25T19:21:44.048Z", "location_count": 7, "location_summary": "Owensboro, Kentucky • Paducah, Kentucky • Jackson, Tennessee + 1 more", "locations": [ { "city": "Owensboro", "state": "Kentucky" }, { "city": "Paducah", "state": "Kentucky" }, { "city": "Jackson", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00503997" }, { "nct_id": "NCT00507767", "title": "Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IVA Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Salivary Gland Cancer", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Salivary Gland Cancer", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Tongue Cancer" ], "interventions": [ { "name": "dasatinib", "type": "DRUG" }, { "name": "pharmacological study", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2007-07", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2014-10-01", "last_synced_at": "2026-06-25T19:21:44.048Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00507767" }, { "nct_id": "NCT00055770", "title": "Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Salivary Gland Squamous Cell Carcinoma", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2002-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-06-25T19:21:44.048Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00055770" }, { "nct_id": "NCT00003856", "title": "Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "temoporfin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Quintiles, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "1998-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-06-25T19:21:44.048Z", "location_count": 7, "location_summary": "Little Rock, Arkansas • Tampa, Florida • Evanston, Illinois + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Tampa", "state": "Florida" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003856" }, { "nct_id": "NCT00036790", "title": "Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Colorectal Cancer", "Head and Neck Cancer", "Leukemia", "Lung Cancer", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic/Myeloproliferative Diseases", "Prostate Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "motexafin gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-06-25T19:21:44.048Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Madison, Wisconsin", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036790" }, { "nct_id": "NCT00984074", "title": "MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "blood-oxygen-level-dependent functional magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "diffusion tensor imaging", "type": "PROCEDURE" }, { "name": "dynamic contrast-enhanced magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "functional magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "radiation therapy treatment planning/simulation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 3, "start_date": "2008-10", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2019-04-24", "last_synced_at": "2026-06-25T19:21:44.048Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00984074" }, { "nct_id": "NCT00003582", "title": "Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma of Unknown Primary", "Head and Neck Cancer" ], "interventions": [ { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 36, "start_date": "1988-05", "completion_date": "1996-12", "has_results": false, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-06-25T19:21:44.048Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003582" }, { "nct_id": "NCT00006106", "title": "ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lip and Oral Cavity Cancer", "Head and Neck Cancer", "Oropharyngeal Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "ONYX-015", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 0, "start_date": "1999-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-06-25T19:21:44.048Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006106" } ] }